Shop By Brands
S
Shop By Brand
S
€101.00
Product information
| Active substances | CALCIUM HYDROXYAPATITE (CaHA), LIDOCAINE |
|---|---|
| Manufacturer | Merz Pharma |
| Pack size | 1 x 1.5ml Pre-Filled Syringe |
| Strength | 0.3% Lidocaine |
We guarantee your order will arrive quickly. Most parcels are delivered within 5–10 business days, ensuring you get the products you need when you need them.
Enjoy personalized support with a dedicated account manager. From product selection to tracking, you’ll always have a trusted partner by your side.
Shop confidently from our selection of medical products. Each item is available for fast, reliable delivery, so your practice stays fully stocked.
We supply only authentic products, backed by full traceability. Every order comes with confidence, transparency, and assurance of verified sourcing.
Radiesse Plus 1.5 ml with Lidocaine is manufactured by Merz Aesthetics, operating under the Merz Pharma Group, a leading global pharmaceutical corporation. The manufacturer offers the RADIESSE product in two main variations:
The formulation consists of the following components:
Device properties:
Each dermal fillers package of Radiesse Plus 1.5 ml with Lidocaine comes with:
Pre-procedure:
During the injection:
Post-procedure:
Radiesse Plus 1.5 ml with Lidocaine typically lasts up to a year, depending on the treatment area and individual patient factors. For best results, patients are recommended to get touch-up treatments every 12 months, which helps maintain the desired effect and promotes continued collagen production.
Common side effects:
Rare side effects:
Radiesse Plus 1.5 ml with Lidocaine treatment is not suitable for several patient groups. The treatment should not be administered to individuals under 18 years of age or women who are pregnant or breastfeeding. Patients with severe allergies, particularly those with a history of anaphylaxis, should avoid this treatment. The product is also contraindicated for those with known hypersensitivity to lidocaine or similar anaesthetic compounds.
Active skin infections or inflammation in the target area preclude treatment until fully resolved. Individuals with bleeding disorders or those currently on anticoagulant therapy should exercise caution. The treatment is not recommended for patients with autoimmune conditions, and those who have recently undergone facial surgery should wait until complete healing before considering this treatment. Additionally, patients with a heightened tendency to develop keloids or hypertrophic scarring may not be suitable candidates.